Among the histological subtypes, estrogen receptor (ER), progesterone receptor (PR), and HER2 status can be used to further delineate patients into ER+/PR+ (60–70% of patients), HER2+ (10–20%), and triple negative breast cancer (TNBC, 15–20%). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.